Latest news with #SII
Yahoo
4 days ago
- Business
- Yahoo
Sprott Stock Glitters Like Gold
Sprott (SII) shows strong technical momentum and just hit a new 52-week high. SII has a 100% technical 'Buy' signal via Barchart. The alternative asset manager also pays a dividend, which could make its shares more attractive. Despite bullish technicals and analyst ratings, SII is volatile and speculative. Valued at $1.66 billion, Sprott (SII) is an alternative asset manager as well as precious metal investor. It provides investors with specialized investment strategies which include exchange-listed products, managed equities, and private equity. It operates through its subsidiaries in Canada, the U.S., and Asia. I found today's Chart of the Day by using Barchart's powerful screening functions. I sorted for stocks with the highest technical buy signals, superior current momentum in both strength and direction, and a Trend Seeker 'buy' signal. I then used Barchart's Flipcharts feature to review the charts for consistent price appreciation. SII checks those boxes. Since the Trend Seeker signaled a buy on April 14, the stock has gained 33.97%. Dollar Rallies as Middle East Tensions Intensify and Stocks Fall Weak Stocks Boost Liquidity Demand for the Dollar Sprott Stock Glitters Like Gold Tired of missing midday reversals? The FREE Barchart Brief newsletter keeps you in the know. Sign up now! SII Price vs. Daily Moving Averages: Editor's Note: The technical indicators below are updated live during the session every 20 minutes and can therefore change each day as the market fluctuates. The indicator numbers shown below therefore may not match what you see live on the website when you read this report. These technical indicators form the Barchart Opinion on a particular stock. Sprott shares hit a new 52-week high on Tuesday, June 17, touching $65.30 in intraday trading. Sprott has a 100% technical 'Buy' signal. The stock closed Tuesday at $64.32, above its 50-day moving average of $54.91. SII has a Weighted Alpha of +66.86. The stock has gained 57% over the past year. SII has its Trend Seeker 'Buy' signal intact. Sprott is trading above its 20, 50 and 100-day moving averages. The stock has made 15 new highs and gained 15.8% in the last month. Relative Strength Index is at 78.82%. The technical support level is $63.95. $1.66 billion market capitalization. Trailing price-earnings ratio of 32.92x. 1.87% dividend yield. Earnings are projected to increase 13.08% this year and an additional 12.26% next year. I don't buy stocks because everyone else is buying, but I do realize that if major firms and investors are dumping a stock, it's hard to make money swimming against the tide. It looks like not only Wall Street analysts, but also many of the popular investing advisory services like this stock. Wall Street analysts tracked by Barchart issued three 'Strong Buy' opinions on this stock CFRA's MarketScope rates the stock a 'Buy.' MorningStar thinks the stock is 13% overvalued. 4,460 investors monitor the stock on Seeking Alpha, which rates the stock a 'Hold.' Today's Chart of the Day highlights Sprott's exceptional price appreciation but is not a buy recommendation — investors should align trades with their risk tolerance and diversification plans. Despite positive technicals, SII stock is volatile and speculative. Strict risk management and stop-loss strategies are essential for potential investors. Today's Chart of the Day was written by Jim Van Meerten. Read previous editions of the daily newsletter here. Additional disclosure: The Barchart of the Day highlights stocks that are experiencing exceptional current price appreciation. They are not intended to be buy recommendations as these stocks are extremely volatile and speculative. Should you decide to add one of these stocks to your investment portfolio it is highly suggested you follow a predetermined diversification and moving stop loss discipline that is consistent with your personal investment risk tolerance. On the date of publication, Jim Van Meerten did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
The Print
5 days ago
- Health
- The Print
How Serum Institute, DNDi tie-up for affordable antibody will bolster global fight against dengue
Additionally, a joint project team will be formed to advance clinical trials, with the goal of registering and deploying the dengue monoclonal antibody in India and other dengue-endemic countries, provided the studies confirm its safety and efficacy, they said in a joint statement. The SII and the Drugs for Neglected Diseases initiative (DNDi) entered into a partnership on 13 June, declaring they will develop a workplan to carry out late stage trials and access activities, along with a joint strategy to raise necessary funds and resources for developing the potential drug candidate, formerly known as VIS513 or Dengueshield. New Delhi: Pune-based Serum Institute of India (SII) has joined hands with an international medical research organisation to accelerate the clinical development of an affordable monoclonal antibody for dengue, a vector-borne disease that has emerged as a major public health challenge for countries like India. Dengue is a climate-sensitive, viral infection transmitted to humans through the bite of infected mosquitoes, mainly aedes aegypti that also spreads pathogens which cause zika and chikungunya fever. While many dengue infections are asymptomatic or produce only mild illness, the virus can in several patients cause more severe disease, and even death. It is estimated that one in 20 people who get sick with dengue get severely ill. Despite the alarmingly rising prevalence and severity of the vector-born disease, there is still no specific treatment available for dengue. The collaboration aims at accelerating the development of an effective and affordable monoclonal antibody treatment for dengue caused by any of the four serotypes of dengue virus, in close cooperation with endemic countries, including Thailand, Malaysia, and Brazil. Despite the… — SerumInstituteIndia (@SerumInstIndia) June 13, 2025 Also Read: India may soon get 1st dengue vaccine, but wait for jab effective against all 4 strains could be longer The latest collaboration The VIS513 is developed by US-based biotechnology company Visterra, a biologic research early-stage clinical development arm of Tokyo-based Otsuka Pharmaceuticals. The VIS513 was later licensed to the SII. The SII has carried out phase 1 and phase 2 trials of the therapy in India, proving its safety and efficacy in a small number of humans. Currently, the pivotal Phase III clinical trial is underway in India, and the collaboration paves way for the expansion of the drug candidate in several other countries where dengue is endemic, the two entities said. Dengue poses a significant threat, with 3.9 billion people at risk and cases more than doubling each year since 2021. The World Health Organization says the actual number of dengue cases globally rose from 5,05,430 cases in 2000 to 5.2 million in 2019. India is among the top 30 countries with the highest burden of dengue, and according to government estimates, among the 20-25 percent of cases where dengue symptoms are clinically apparent, children are at a significantly higher risk of hospitalisation and mortality. This year, the country registered 12,043 dengue cases and six deaths till March, according to the National Centre for Vector Borne Disease Control statistics. Last year, 2,33,519 cases and 297 deaths were reported but experts underline the actual burden of the disease is much higher. 'India reports tens of thousands of dengue cases every year, with outbreaks occurring every two to three years in different states,' said Dr Kavita Singh, the Asia Continental Lead & Director South Asia, DNDi. What is deeply concerning is that dengue is no longer confined to historically endemic regions but is rapidly expanding into newer states, she added. 'Addressing this growing threat demands a multi-pronged approach, including strengthened vector control, surveillance, community awareness and, critically, the development of effective treatments and diagnostics,' Singh also said. A 2024 dengue bulletin by the WHO said that the highest number of dengue cases was recorded in 2023, affecting over 80 countries in all regions of the WHO. In 2023, a combination of ongoing dengue transmission and a significant surge in cases led to a record-breaking 6.5 million infections and over 7,300 deaths globally. New monoclonal antibody offers help Monoclonal antibodies, sometimes also called passive immunisation, are special types of proteins called antibodies which are made in laboratories. Dengue is caused by any of four dengue virus (DENV) serotypes (DENV 1 to 4), each of which can cause minor dengue fever or severe dengue. Dengue can be anything from an infection without symptoms, a mild fever or a severe fever with musculoskeletal pain to haemorrhagic fever (low platelets leading to bleeding) and dengue shock syndrome (severe form of dengue infection that can lead to circulatory collapse). The latter two can be very severe and result in death if not recognised and treated early. And these two conditions usually happen, not in the first but in subsequent infection, when the dengue virus strain is different from the one that caused the earlier infection. According to Dr R.R. Dutta, the head of internal medicine with Paras Health in Gurugram, medical practitioners need to develop customised treatment plans which focus on avoiding severe disease outcomes such as dengue hemorrhagic fever and shock syndrome in patients who experience severe symptoms. Dr Manisha Arora, director, internal medicine with C K Birla Hospital in Delhi, pointed out that unlike bacterial infections, where antibiotics can attack the root cause and cure the disease, dengue, being a viral infection, lacks such a targeted treatment. If we had a specific antiviral for dengue, it would help in directly attacking the virus, thereby reducing the risk of complications and improving patient outcomes, said the clinician. 'Unfortunately, in the absence of such antivirals, doctors are limited to providing only supportive care, such as fluid management, monitoring vital signs, and treating complications as they arise,' Arora stressed. The current treatment regime for severe dengue patients depends heavily on early detection and timely intervention, but it doesn't address the underlying virus. 'The lack of specific antivirals limits our ability to prevent disease progression, especially in severe cases. If an effective antiviral existed, it could potentially reduce hospitalisations, lower the risk of long-term health issues and ultimately save more lives,' Arora also said. The monoclonal antibody candidate by the SII, as per available information, has shown efficacy against all dengue virus serotypes with no serious adverse events. The therapy candidate, designed to be effective against all four DENV serotypes, works by binding to a specific part of DENV called the envelope protein domain III, known for its role in viral entry into host cells and its immunogenicity. The results from a phase 1 clinical trial of the drug involving 40 participants in India—based on follow-ups lasting 85 days—whihc was published in the Lancet last year, showed the drug was found effective and safe in early testing. AV-1, another investigational human monoclonal antibody developed by US-based company AbViro, is also in a similar stage of development and is undergoing safety and efficacy trials across various countries. A dengue vaccine by Japanese pharma giant Takeda, approved by some other countries, is also undergoing trials in India to generate local safety and efficacy data ahead of its regulatory approval in the country. (Edited by Ajeet Tiwari) Also Read: India sees alarming rise in dengue cases even before peak season, steady increase over past 4 years
The Sun
5 days ago
- Health
- The Sun
‘Timely' alliance to develop effective dengue treatment
KUALA LUMPUR: Malaysia has welcomed a new international partnership to develop the world's first specific treatment for dengue, marking World Dengue Day with a reaffirmed commitment to addressing one of the country's most persistent and deadly public health threats. The initiative follows the signing of a memorandum of understanding (MoU) between the Serum Institute of India (SII) and the not-for-profit medical research organisation Drugs for Neglected Diseases initiative (DNDi), formalising their commitment to accelerate the development of a monoclonal antibody therapy for dengue. 'The treatment aims to be effective across all four dengue virus serotypes and accessible to low and middle-income countries,' DNDi said in a statement. Malaysia has expressed strong support for the initiative, which aims to make effective treatment accessible to low and middle-income countries hardest hit by the disease. Health Ministry Deputy Director-General (research and technical assistance) Datuk Dr Nor Fariza Ngah said the partnership between DNDi and the Serum Institute of India is both timely and strategic. She said Malaysia supports the collaboration as a means to accelerate the development and access to dengue treatment, especially for countries like Malaysia where the disease remains endemic. 'The signing of the MoU marks a pivotal step forward in the global fight against dengue. The development of a monoclonal antibody treatment represents a promising new frontier in dengue care, with the potential to save lives and reduce the burden of severe disease, especially in a country like Malaysia, where we average over 90,000 cases a year,' she added. Dengue remains one of Malaysia's most pressing public health threats, with more than 120,000 cases and 117 deaths reported in 2024 alone. Recurring outbreaks put a significant strain on healthcare infrastructure, particularly in densely populated urban centres. Currently, there is no approved antiviral treatment for dengue. Management of the disease is limited to supportive care and severe cases often require hospitalisation. The proposed monoclonal antibody therapy is designed to be administered early in the infection to prevent the disease from progressing to severe dengue, which can be life-threatening. The investigational therapy, previously known as VIS513, targets all four dengue virus serotypes and has shown promising results in early trials. As part of the agreement, the next phase of clinical development will include multinational Phase III trials in dengue-endemic countries, including Malaysia. DNDi dengue global programme head Dr André Siqueira said the treatment could be a game-changer. 'We urgently need a therapeutic option for dengue that is effective, scalable and affordable. ' This collaboration is a critical step toward that goal,' he said.
The Sun
5 days ago
- Health
- The Sun
Malaysia backs global push for first dengue treatment
KUALA LUMPUR: Malaysia has welcomed a new international partnership to develop the world's first specific treatment for dengue, marking World Dengue Day with a reaffirmed commitment to addressing one of the country's most persistent and deadly public health threats. The initiative follows the signing of a memorandum of understanding (MoU) between the Serum Institute of India (SII) and the not-for-profit medical research organisation Drugs for Neglected Diseases initiative (DNDi), formalising their commitment to accelerate the development of a monoclonal antibody therapy for dengue. 'The treatment aims to be effective across all four dengue virus serotypes and accessible to low and middle-income countries,' DNDi said in a statement. Malaysia has expressed strong support for the initiative, which aims to make effective treatment accessible to low and middle-income countries hardest hit by the disease. Health Ministry Deputy Director-General (research and technical assistance) Datuk Dr Nor Fariza Ngah said the partnership between DNDi and the Serum Institute of India is both timely and strategic. She said Malaysia supports the collaboration as a means to accelerate the development and access to dengue treatment, especially for countries like Malaysia where the disease remains endemic. 'The signing of the MoU marks a pivotal step forward in the global fight against dengue. The development of a monoclonal antibody treatment represents a promising new frontier in dengue care, with the potential to save lives and reduce the burden of severe disease, especially in a country like Malaysia, where we average over 90,000 cases a year,' she added. Dengue remains one of Malaysia's most pressing public health threats, with more than 120,000 cases and 117 deaths reported in 2024 alone. Recurring outbreaks put a significant strain on healthcare infrastructure, particularly in densely populated urban centres. Currently, there is no approved antiviral treatment for dengue. Management of the disease is limited to supportive care and severe cases often require hospitalisation. The proposed monoclonal antibody therapy is designed to be administered early in the infection to prevent the disease from progressing to severe dengue, which can be life-threatening. The investigational therapy, previously known as VIS513, targets all four dengue virus serotypes and has shown promising results in early trials. As part of the agreement, the next phase of clinical development will include multinational Phase III trials in dengue-endemic countries, including Malaysia. DNDi dengue global programme head Dr André Siqueira said the treatment could be a game-changer. 'We urgently need a therapeutic option for dengue that is effective, scalable and affordable. ' This collaboration is a critical step toward that goal,' he said.
Time of India
14-06-2025
- Health
- Time of India
Serum Institute of India holds 'Conquer HPV and Cancer Conclave' in Visakhapatnam
Visakhapatnam: Serum Institute of India (SII) held the ' Conquer HPV and Cancer Conclave ' in Visakhapatnam, Andhra Pradesh, to spread awareness regarding the sexually transmitted infection Human Papillomavirus (HPV). Dr B. Murli Santosh, consultant paediatrician and neonatologist, attended the conclave on Friday. Speaking to reporters, he said, "...Cervical cancer is the second most common cancer in Indian women, not only Indian women, across the globe, and annually, as per the statistics, close to 1,00,000 deaths are reported in India." Emphasising the HPV vaccine, he added, "So one thing that the public needs to know is that there is a vaccine by which we can prevent this cancer and which has been readily available for the last 10 to 15 years. But the problem in India is that the awareness among the public... various reasons, cost constraints, or various misconceptions. The amount of vaccinations which the public are getting is very less. Now we are having Indian-made vaccines which are easily available and cost-effective. And once we can effectively vaccinate, this cancer is almost hundred per cent preventable. So, most of the time, we recommend early-age vaccinations, preferably at 9 to 14 years, in which they receive two doses, and at 15 to 45 years, in which they receive three doses. And once they receive the vaccination, most of the time they get 99% to 100% protection against these cancers." Speaking to ANI, Dr R Vidya Rama, professor of obstetrics and gynaecology in Andhra Medical College and the visiting consultant, Medicover Women and Child Hospitals, said, "We have gathered here to talk about HPV vaccination . What are the recent changes in HPV vaccination? Previously this vaccination was advocated for girls to prevent cervical cancer, but now it's been proven that HPV is not only for cervical cancer but also for cancers in men, it is penile cancer, and it is also a cause for anal cancers and oropharyngeal cancers in both men and women." Elaborating on vaccination, Dr Rama said, "So ideally, the vaccination to prevent these cancers should be given before sexual exposure. The best time to take the vaccine is between 9 and 14 years. When the immune response and protection will be maximum, and only two doses would be enough. But, if the girls and boys miss out their vaccination at the age below 15 years, they can take the vaccination even after 15 years. Previously, we had a vaccine made by an MNC only, which is a very effective and safe vaccine, but the only disadvantage with that particular vaccine is costly. Now we have a vaccine, a quadrivalent vaccine, which has been made by the Serum Institute of biggest advantage is we have a vaccine which comes with a very affordable cost that is very important for our country to protect our girls and boys with a vaccine." SII, in collaboration with India's Department of Biotechnology (DBT) and Biotechnology Industry Research Assistance Council (BIRAC), recently developed India's first indigenous gender neutral quadrivalent HPV vaccine, Cervavac. The medical firm is holding a nationwide conclave to spread awareness regarding the vaccine.
